Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
25.16
-0.58 (-2.25%)
At close: Feb 21, 2025, 4:00 PM
25.30
+0.14 (0.56%)
After-hours: Feb 21, 2025, 7:46 PM EST
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $168.57M in the quarter ending September 30, 2024, with 2.83% growth. This brings the company's revenue in the last twelve months to $694.96M, up 4.40% year-over-year. In the year 2023, Pacira BioSciences had annual revenue of $674.98M with 1.22% growth.
Revenue (ttm)
$694.96M
Revenue Growth
+4.40%
P/S Ratio
1.68
Revenue / Employee
$976,063
Employees
712
Market Cap
1.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PCRX News
- 2 days ago - Pacira to Report 2024 Financial Results on Thursday February 27, 2025 - GlobeNewsWire
- 2 days ago - Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX - PRNewsWire
- 2 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - GlobeNewsWire
- 6 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Accesswire
- 16 days ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights – PCRX - GlobeNewsWire
- 23 days ago - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - GlobeNewsWire
- 4 weeks ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit – PCRX - GlobeNewsWire